Original-Research: NFON AG - from NuWays AG
Classification of NuWays AG to NFON AG
Company Name: NFON AG
ISIN: DE000A0N4N52
Reason for the research: Update
Recommendation: Kaufen
from: 24.05.2024
Target price: EUR 11.70
Target price on sight of: 12 Monaten
Last rating change:
Analyst: Philipp Sennewald
Strong Q1 displays ongoing operational improvements; chg.
NFON released Q1 results, showing a continuously strong recurring revenue ratio as well as further profitability improvements. In detail:
Q1 recurring revenues increased by 2.8% yoy to € 19.9m (eNuW: € 20.4m) and remained at a continuously strong ratio of 93.6% as total sales came in at € 21.1m. Sales growth was predominantly driven by an increased seat base (+2% to 659k) as well as the cross-selling referring to the company’s premiums solutions. This also becomes visible in the blended ARPU (adjusted for SIP-Trunk sales), which improved to € 9.82 vs € 9.80 in Q1’23.
While we expect seat growth to remain at a stable pace throughout the year, ARPU is seen to further improve driven by (1) premium solutions like CC Hub, where ARPU levels of € 30-40 can be achieved, as well as (2) price indexation effects which came into effect in April.
Profitability further improved, as adjusted EBITDA increased disproportionately by 43% yoy to € 2.8m (eNuW: € 2.6m; reported EBITDA at € 2.7m). This was partly driven by a slightly improved gross margin of 84.1% (+0.3pp yoy) but more importantly by ongoing improvements on the personnel (-2pp yoy sales ratio) and other OpEx (-1.5pp yoy; mostly sales & marketing) level. Q1 EBIT came in at € 0.7m while FCF was slightly positive with € 0.2m.
Going forward, we expect continuous improvements based on the mentioned development of the salesmix as well as further efficiency gains, especially in connection with the integration of DTS, which is seen to crease significant synergies from H2 onwards.
On this basis, management confirmed the FY guidance, targeting recurring revenue growth in the midto upper-single-digit-% range (eNuW new: +5.3%) at a recurring revenue ratio of >90% (eNuW new: 93.9%) as well as an adjusted EBITDA in the range of € 10-12m (eNuW new: € 11.5m).
That said, valuation remains attractive, in our view, as shares are trading on a mere 1.2 EV/Sales ‘24e (9.9x EV/EBITDA). We therefore reiterate BUY with an unchanged PT of € 11.70 based on DCF. NFON remains part of our NuWays Alpha List.
You can download the research here:
http://www.more-ir.de/d/29883.pdf
For additional information visit our website
www.nuways-ag.com/research.
Contact for questions
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++
-------------------transmitted by EQS Group AG.-------------------
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
